THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 93 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2018. The put-call ratio across all filers is 0.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $164 | -35.4% | 18,994 | -22.5% | 0.00% | – |
Q2 2023 | $254 | -30.4% | 24,506 | -27.2% | 0.00% | – |
Q1 2023 | $365 | -25.5% | 33,671 | -22.9% | 0.00% | -100.0% |
Q4 2022 | $490 | -99.9% | 43,654 | -0.0% | 0.00% | 0.0% |
Q3 2022 | $443,000 | +12.4% | 43,659 | +0.3% | 0.00% | 0.0% |
Q2 2022 | $394,000 | +15.2% | 43,518 | +21.5% | 0.00% | – |
Q1 2022 | $342,000 | -13.6% | 35,817 | +0.0% | 0.00% | – |
Q4 2021 | $396,000 | +85.0% | 35,806 | +23.7% | 0.00% | – |
Q3 2021 | $214,000 | -69.1% | 28,951 | -39.3% | 0.00% | -100.0% |
Q2 2021 | $693,000 | -18.0% | 47,694 | +15.2% | 0.00% | 0.0% |
Q1 2021 | $845,000 | +14.8% | 41,400 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $736,000 | +20.3% | 41,400 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $612,000 | -29.6% | 41,400 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $869,000 | -10.9% | 41,400 | -1.9% | 0.00% | 0.0% |
Q1 2020 | $975,000 | -10.8% | 42,200 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $1,093,000 | +16.6% | 42,200 | -12.3% | 0.00% | 0.0% |
Q3 2019 | $937,000 | +36.4% | 48,100 | +14.3% | 0.00% | 0.0% |
Q2 2019 | $687,000 | -28.0% | 42,100 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $954,000 | -11.4% | 42,100 | 0.0% | 0.00% | -50.0% |
Q4 2018 | $1,077,000 | -28.8% | 42,100 | -9.1% | 0.00% | 0.0% |
Q3 2018 | $1,513,000 | +44.1% | 46,300 | 0.0% | 0.00% | +100.0% |
Q2 2018 | $1,050,000 | -6.5% | 46,300 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $1,123,000 | -13.0% | 46,300 | 0.0% | 0.00% | -50.0% |
Q4 2017 | $1,291,000 | -18.5% | 46,300 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $1,585,000 | -14.1% | 46,300 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $1,845,000 | +18.2% | 46,300 | +9.2% | 0.00% | 0.0% |
Q1 2017 | $1,561,000 | +28.2% | 42,401 | +11.0% | 0.00% | 0.0% |
Q4 2016 | $1,218,000 | -12.0% | 38,200 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $1,384,000 | +120.0% | 38,200 | +37.9% | 0.00% | +100.0% |
Q2 2016 | $629,000 | +20.7% | 27,700 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $521,000 | +36.4% | 27,700 | +18.9% | 0.00% | 0.0% |
Q4 2015 | $382,000 | +49.2% | 23,300 | 0.0% | 0.00% | – |
Q3 2015 | $256,000 | -26.6% | 23,300 | -13.2% | 0.00% | -100.0% |
Q2 2015 | $349,000 | – | 26,830 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |